Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyModa Health BRCA/myChoice CDx Coverage Update | Op…
    Ask Trek AI about this page
    CurrentModa HealthPolicy N/A

    BRCA Testing (BRACAnalysis CDx; myChoice CDx) (Myriad)

    Customize your policy alerts

    Sign up for all Moda Health policy alerts

    Know when Moda Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior-authorization criteria for Myriad's BRACAnalysis CDx (germline) and myChoice CDx (tumor/somatic) tests for members being considered for specific targeted therapies, including required documentation for prior authorization.

    Policy Summary
    PayerModa Health
    PolicyBRCA Testing (BRACAnalysis CDx; myChoice CDx) (Myriad)
    Policy CodePolicy N/A
    Change TypeNo material clinical changes
    Effective DateMar 1, 2026
    Last ReviewFeb 25, 2026
    Next Review DateFeb 25, 2026
    Key ActionObtain prior authorization and submit chart notes, previous treatments, and the treatment plan.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2named assays covered
    18+minimum age
    81162covered CPT
    81164/66/67not covered CPTs
    Prior auth

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    authorization required

    Coverage Criteria and Indications

    BRACAnalysis_CDx - Covered Indications

    BRACAnalysis_CDx will be covered to plan limitations for members 18 years or older who meet ONE of the following clinical scenarios:

    Ovarian cancer (including epithelial ovarian, fallopian tube, or primary peritoneal): Member has ovarian cancer (including epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer) AND all of: (i) treated with either three or more prior lines of chemotherapy OR first-line platinum-based chemotherapy with complete or partial response; (ii) no previous testing for BRCA mutations; (iii) member is being considered for treatment or maintenance with olaparza (olaparib) or Rubraca (rucaparib).

    Based on II.A.a.i-iii in policy

    Metastatic HER2-negative breast cancer: Member has metastatic, HER2-negative breast cancer AND all of: (i) previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting (regardless of family history); (ii) no previous testing for BRCA mutations; (iii) member is being considered for treatment with Lynparza (olaparib) or Talzenna (talazoparib).

    Based on II.A.b.i-iii in policy

    Metastatic pancreatic carcinoma: Member has metastatic pancreatic carcinoma whose disease has not progressed following the first line of treatment and is being considered for maintenance treatment with olaparib (Lynparza).

    Based on II.A.c in policy

    Metastatic prostate cancer: Member has metastatic prostate cancer and is being considered for treatment with olaparib (Lynparza).

    Based on II.A.d in policy

    myChoice CDx - Covered Indications

    myChoice CDx will be covered to plan limitations for members who meet ALL the following:

    myChoice CDx general eligibility: Member is 18 years of age or older AND has advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer AND meets at least one of the therapy-related conditions listed below.

    Based on II.B.a and II.B.b in policy

    Therapy-related conditions: i. Treated with three or more lines of chemotherapy and being considered for treatment with niraparib (Zejula); OR ii. In complete or partial response to two or more lines of platinum-based chemotherapy and being considered for maintenance treatment with niraparib (Zejula); OR iii. Being considered for first-line maintenance treatment with olaparib (Lynparza) in combination with bevacizumab.

    Based on II.B.b.i-iii in policy

    Use of CPT codes 81164, 81166, and 81167 for BRCA testing is explicitly listed as not covered by this policy.

    Specific Covered Indications

    Germline BRCA testing (BRACAnalysis CDx) - Covered Indications

    Germline BRCA testing (BRACAnalysis CDx) - covered scenarios: Covered for members 18 years or older with one of the following clinical scenarios: a) Ovarian cancer (including epithelial ovarian, fallopian tube or primary peritoneal cancer) who have either had three or more prior lines of chemotherapy OR received first-line platinum-based chemotherapy with complete or partial response, have no previous BRCA testing, and are being considered for treatment/maintenance with olaparip (Lynparza) or Rubraca (rucaparib); b) Metastatic, HER2-negative breast cancer previously treated with chemotherapy (neoadjuvant, adjuvant, or metastatic setting), with no previous BRCA testing, and being considered for Lynparza (olaparib) or Talzenna (talazoparib); c) Metastatic pancreatic carcinoma with disease not progressed after first-line treatment and being considered for maintenance olaparib (Lynparza); d) Metastatic prostate cancer being considered for treatment with olaparib (Lynparza).

    Reflects II.A.a-d in policy

    Somatic tumor BRCA testing and HRD assessment (myChoice CDx) - Covered Indications

    myChoice CDx tumor BRCA/HRD testing - eligibility: Member is 18 years or older AND has advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer AND meets at least one of the therapy-related conditions below.

    CPT / HCPCS Coding

    Covered CPT/HCPCS CodesmixedCovered
    81162BRCA1, BRCA2 gene analysis; full sequence analysis and full duplication/deletion analysis
    0172UOncology (solid tumor as indicated by the label), somatic mutation analysis of BRCA1 and BRCA2 and analysis of homologous recombination deficiency pathways, DNA, FFPE tissue, algorithm quantifying tumor genomic instability score
    Not covered CPT CodesCPTNot Covered
    81164BRCA1, BRCA2 gene analysis; full duplication/deletion analysis (detection of large gene rearrangements)
    81166BRCA1 gene analysis; full duplication/deletion analysis (detection of large gene rearrangements)
    81167BRCA2 gene analysis; full duplication/deletion analysis (detection of large gene rearrangements)

    Prior Authorization, Documentation, and Denial Risks

    Prior Authorization

    Prior authorization required for BRCA/myChoice testing

    Prior authorization is required for BRACAnalysis CDx (germline) and myChoice CDx (tumor) testing; requests must be limited to the clinical indications listed in the policy tied to consideration of targeted therapies (e.g., Lynparza, Rubraca, Talzenna, Niraparib).

    • Submit a prior authorization request for CPT 81162 or HCPCS 0172U when applicable.
    • Coverage is limited to the specified clinical scenarios in Section II (BRACAnalysis_CDx and myChoice CDx criteria).
    Step Therapy

    Step-therapy: none specified

    No step-therapy sequencing or additional step requirements are specified in the policy for BRACAnalysis CDx or myChoice CDx.

    Eligibility Requirements

    Determine member eligibility by confirming the member is 18 years or older and that the clinical situation meets the policy’s specified indications for either BRACAnalysis CDx (germline testing tied to consideration of PARP inhibitor therapy) or myChoice CDx (tumor testing and homologous recombination deficiency assessment tied to niraparib or olaparib/bevacizumab decisions). Prior testing status (e.g., no previous BRCA testing where required) and the specific therapy-related criteria listed for each indication must be documented.

    Definitions

    Genomic Instability Score (GIS)
    DefinitionGenomic Instability Score (GIS) — an algorithmic measurement that combines loss of heterozygosity (LOH), telomeric allelic imbalance (TAI), and large-scale state transitions (LST).
    Purpose in myChoice CDxComputed by the myChoice CDx assay on DNA from FFPE tumor tissue to assess homologous recombination deficiency and help identify ovarian cancer patients who may be eligible for niraparib therapy.
    ComponentsLOH (loss of heterozygosity), TAI (telomeric allelic imbalance), and LST (large-scale state transitions) are the three genomic features quantified and combined into the GIS algorithm.
    Assay contextDetermined as part of the FDA-authorized myChoice CDx next-generation sequencing tumor test that also detects BRCA1/2 single nucleotide variants, indels, and large rearrangements.
    Specimen typeCalculated from DNA isolated from formalin-fixed paraffin-embedded (FFPE) tumor tissue specimens used by myChoice CDx.

    Background

    BRACAnalysis CDx is Myriad’s germline BRCA1/2 assay performed on blood DNA to detect single nucleotide variants, small insertions/deletions, and large rearrangements to identify patients eligible for PARP inhibitor therapy. myChoice CDx is an FDA-authorized tumor-based NGS assay performed on FFPE tissue that assesses BRCA1/2 variants and computes a Genomic Instability Score (GIS) — an algorithmic measure of loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions — to identify ovarian cancer patients who may be eligible for niraparib or olaparib plus bevacizumab as indicated.

    Not Covered

    Testing billed using CPT codes 81164, 81166, or 81167 is not covered under this policy and may result in denial of claim payment.

    Policy Summary
    PayerModa Health
    PolicyBRCA Testing (BRACAnalysis CDx; myChoice CDx) (Myriad)
    Policy CodePolicy N/A
    Change TypeNo material clinical changes
    Effective DateMar 1, 2026
    Last ReviewFeb 25, 2026
    Next Review DateFeb 25, 2026
    Key ActionObtain prior authorization and submit chart notes, previous treatments, and the treatment plan.
    SourceLink
    On This Page
    Coverage Criteria and IndicationsSpecific Covered IndicationsCPT / HCPCS CodingPrior Authorization, Documentation, and Denial RisksEligibility RequirementsDefinitionsBackgroundNot Covered

    Based on II.B.a and II.B.b in policy

    Therapy-related conditions for myChoice CDx: i) Treated with three or more lines of chemotherapy and being considered for niraparib (Zejula); OR ii) In complete or partial response to two or more lines of platinum-based chemotherapy and being considered for maintenance niraparib (Zejula); OR iii) Being considered for first-line maintenance with olaparib (Lynparza) plus bevacizumab.

    Based on II.B.b.i-iii in policy

    Documentation Required

    Required documentation for prior authorization

    Required documentation must be submitted with the prior authorization request: chart notes, previous treatments, and the treatment plan.

    • Include documentation that supports the member meets the specific clinical indication tied to consideration of the named targeted therapy.
    • Attach prior treatment history (e.g., number and type of chemotherapy lines or response to platinum-based therapy) as applicable to the indication.
    Denial Risk

    Denial risk if clinical criteria are not met

    Testing requests that do not meet the coverage criteria (the specific clinical scenarios and therapy considerations in Section II) may be denied.

    • Verify member age (18+) and the exact therapy-related conditions listed for BRACAnalysis_CDx or myChoice CDx before submitting authorization.
    Denial Risk

    Denial risk for non-covered CPT codes (81164, 81166, 81167)

    Claims billed with CPT codes 81164, 81166, or 81167 for BRCA testing are not covered and may be denied.

    • Use covered codes (e.g., 81162 or 0172U where appropriate) rather than 81164/81166/81167.
    • Do not submit prior authorization or claims using 81164, 81166, or 81167 for coverage consideration under this policy.